Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2021

Open Access 01-12-2021 | Lymphoma | Review

How we treat mature B-cell neoplasms (indolent B-cell lymphomas)

Authors: Melissa Lumish, Lorenzo Falchi, Brandon S. Imber, Michael Scordo, Gottfried von Keudell, Erel Joffe

Published in: Journal of Hematology & Oncology | Issue 1/2021

Login to get access

Abstract

Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an excellent prognosis, and in many, treatment can be deferred for years. However, some patients will have an accelerated course and may experience transformation into aggressive lymphomas. In this review, we focus on management concepts shared across iNHLs, as well as histology-specific strategies. We address open questions in the field, including the influence of genomics and molecular pathway alterations on treatment decisions. In addition, we review the management of uncommon clinical entities including nodular lymphocyte-predominant Hodgkin lymphoma, hairy cell leukemia, splenic lymphoma and primary lymphoma of extranodal sites. Finally, we include a perspective on novel targeted therapies, antibodies, antibody–drug conjugates, bispecific T cell engagers and chimeric antigen receptor T cell therapy.
Literature
1.
Magnano L, et al. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. Br J Haematol. 2019;185:480–91.PubMedCrossRef
2.
Tarella C, et al. Life expectancy in follicular lymphoma is mainly determined by response to first LINE treatment: a long-term survey on 597 patients. Blood. 2015;126:3989–3989.CrossRef
3.
Sarkozy C, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37:144–52.PubMedCrossRef
4.
van de Schans SAM, van Steenbergen LN, Coebergh JWW, Janssen-Heijnen MLG, van Spronsen DJ. Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands. Haematologica. 2014;99:339–45.PubMedPubMedCentralCrossRef
5.
6.
Lobetti-Bodoni C, et al. The importance of age in prognosis of follicular lymphoma: clinical features and life expectancy of patients younger than 40 years. Blood. 2011;118:1593–1593.CrossRef
7.
Batlevi CL, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020a;10:74.PubMedPubMedCentralCrossRef
8.
Link BK, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: A report from the university of Iowa/mayo clinic specialized program of research excellence molecular epidemiology resource. J Clin Oncol. 2013;31:3272–8.PubMedPubMedCentralCrossRef
9.
Sortais C, et al. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. Ann Hematol. 2020;99:1595–604.PubMedCrossRef
10.
Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:1454–9.CrossRef
11.
Brice P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15:1110–7.PubMedCrossRef
12.
Ardeshna KM, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516–22.PubMedCrossRef
13.
14.
Yang JC, Yahalom J. Early-stage follicular lymphoma: what is the preferred treatment strategy? J Clin Oncol. 2018;36:2904–6.PubMedCrossRef
15.
Matasar MJ, et al. Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs. Oncologist. 2019;24:e1236–50.PubMedPubMedCentralCrossRef
16.
Diamond B, Kumar A. Mantle cell lymphoma: current and emerging treatment strategies and unanswered questions. Hematol Oncol Clin North Am. 2019;33:613–26.PubMedCrossRef
17.
18.
Ayyappan S, William BM. Marginal zone lymphoma: clinicopathologic variations and approaches to therapy. Curr Oncol Rep. 2018;20:33.PubMedCrossRef
19.
20.
Tobin JWD, et al. Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Adv. 2019;3:2804–11.PubMedPubMedCentralCrossRef
21.
Katzenberger T, et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood. 2009;113:1053–61.PubMedCrossRef
22.
Staiger AM, et al. Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles. Blood. 2020;135:181–90.PubMedCrossRef
23.
Leich E, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 2009;114:826–34.PubMedPubMedCentralCrossRef
24.
Leich E, et al. Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia. 2016;30:854–60.PubMedCrossRef
25.
Soubeyran P, et al. Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol. 1996;7:713–8.PubMedCrossRef
26.
Schmatz AI, et al. Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol. 2011;29:1445–51.PubMedCrossRef
27.
Beaton C, Davies M, Beynon J. The management of primary small bowel and colon lymphoma-a review. Int J Colorectal Dis. 2012;27:555–63.PubMedCrossRef
28.
Eichenauer DA, et al. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin study group. J Clin Oncol. 2015;33:2857–62.PubMedCrossRef
29.
Lowry L, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100:86–92.PubMedCrossRef
30.
Wilder RB, et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol. 2001;51:1219–27.CrossRef
31.
Brady JL, et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019a;133:237–45.PubMedCrossRef
32.
Lo A, et al. Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study. Blood. 2020;136:1006–10.PubMedCrossRef
33.
34.
Barzenje DA, et al. Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2017;58:623–32.PubMedCrossRef
35.
36.
Ruella M, et al. Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I–II follicular lymphoma: results of a multicenter study. Int J Radiat Oncol Biol Phys. 2016;94:783–91.PubMedCrossRef
37.
Friedberg JW, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National Lymphocare Study. J Clin Oncol. 2012;30:3368–75.PubMedPubMedCentralCrossRef
38.
Illidge T, et al. Modern radiation therapy for nodal non-hodgkin lymphoma—target definition and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol. 2014;89:49–58.CrossRef
39.
Yahalom J, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92:11–31.PubMedCrossRef
40.
Tsang RW, Gospodarowicz MK. Low-grade non-hodgkin lymphomas. Semin Radiat Oncol. 2007;17:198–205.PubMedCrossRef
41.
Guadagnolo BA, et al. Long-term outcome and mortality trends in early-stage, Grade 1–2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol. 2006;64:928–34.CrossRef
42.
Au WY, et al. Incidence of second neoplasms in patients with MALT lymphoma: no increase in risk above the background population. Ann Oncol Off J Eur Soc Med Oncol. 1999;10:317–21.CrossRef
43.
Goda JS, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116:3815–24.PubMedCrossRef
44.
Krikorian JG, Portlock CS, Cooney P, Rosenberg SA. Spontaneous regression of non-Hodgkin’s lymphoma: a report of nine cases. Cancer. 1980;46:2093–9.PubMedCrossRef
45.
Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation. Cancer. 2010;116:3843–51.PubMedCrossRef
46.
47.
Barzenje DA, et al. Radiotherapy compared to other strategies in the treatment of stage I/II follicular lymphoma: a study of 404 patients with a median follow-up of 15 years. PLoS ONE. 2015;10:e0131158.PubMedPubMedCentralCrossRef
48.
Anderson T, et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer. 1982;50:2699–707.PubMedCrossRef
49.
Choi SI, et al. Prevalence and implications of bone marrow involvement in patients with gastric mucosa-associated lymphoid tissue lymphoma. Gut Liver. 2018;12:278–87.PubMedPubMedCentralCrossRef
50.
Brandwein-Gensler MS, Mahadevia P, Gnepp DR. Chapter 13—hematopoietic lesions—diagnostic surgical pathology of the head and neck. 2nd ed. Philadelphia: W.B. Saunders; 2009. p. 933–74.
51.
Arcaini L, et al. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol. 2007;136:301–4.PubMedCrossRef
52.
Carbone A, et al. Monocytoid B-cell lymphoma with bone marrow and peripheral blood involvement at presentation. Am J Clin Pathol. 1989;92:228–36.PubMedCrossRef
53.
Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. J Clin Oncol. 1998;16:2780–95.PubMedCrossRef
54.
Cohen PL, Kurtin PJ, Donovan KA, Hanson CA. Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol. 1998;101:302–10.PubMedCrossRef
55.
Pittaluga S, et al. Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma. Leuk Lymphoma. 1996;21:115–25.PubMedCrossRef
56.
Vasef MA, Medeiros LJ, Koo C, McCourty A, Brynes RK. Cyclin D1 immunohistochemical staining is useful in distinguishing mantle cell lymphoma from other low-grade B-cell neoplasms in bone marrow. Am J Clin Pathol. 1997;108:302–7.PubMedCrossRef
57.
Wasman J, Rosenthal NS, Farhi DC. Mantle cell lymphoma. Morphologic findings in bone marrow involvement. Am J Clin Pathol. 1996;106:196–200.PubMedCrossRef
58.
Pulsoni A, et al. Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy. Br J Haematol. 2020;188:249–58.PubMedCrossRef
59.
Kato D, et al. The clinical impact of minimal bone marrow involvement on the outcome of patients with follicular lymphoma. Blood. 2016;128:2966–2966.CrossRef
60.
Federico M, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555–62.PubMedCrossRef
61.
Binkley MS, et al. Salvage treatment and survival for relapsed follicular lymphoma following primary radiation therapy: a collaborative study on behalf of ILROG. Int J Radiat Oncol Biol Phys. 2019;104:522–9.PubMedPubMedCentralCrossRef
62.
Gunther JR, et al. Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leuk Lymphoma. 2020;61:171–5.PubMedCrossRef
63.
64.
MacManus M, et al. Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J Clin Oncol. 2018;36:2918–25.PubMedCrossRef
65.
Seymour JF, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I–II indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21:2115–22.PubMedCrossRef
66.
Brady JL, et al. Definitive radiotherapy for localized follicular lymphoma staged by18F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019b;133:237–45.PubMedCrossRef
67.
Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;311:1471–5.PubMedCrossRef
68.
Young RC, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988;25:11–6.PubMed
69.
Morabito F, et al. Prospective study of indolent non-follicular non-Hodgkin’s lymphoma: validation of Gruppo Italiano Per Lo Studio Dei Linfomi (GISL) prognostic criteria for watch and wait policy. Leuk Lymphoma. 2002;43:1933–8.PubMedCrossRef
70.
Barta SK, et al. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: a trial of the ECOG-ACRIN cancer research group (E1496). Cancer. 2016;122:2996–3004.PubMedCrossRef
71.
72.
Kumar A, et al. Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. Haematologica. 2019;104:e163–6.PubMedPubMedCentralCrossRef
73.
Kyle RA, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. In: Seminars in oncology. vol. 30. W.B. Saunders; 2003. p. 116–20.
74.
Cheah CY, Opat S, Trotman J, Marlton P. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. Intern Med J. 2019;49:1070–80.PubMedCrossRef
75.
Ardeshna KM, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. Lancet Oncol. 2014;15:424–35.PubMedCrossRef
76.
Kahl BS, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol E4402. J Clin Oncol. 2014;32:3096–102.PubMedPubMedCentralCrossRef
77.
Williams ME, et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016;173:867–75.PubMedPubMedCentralCrossRef
78.
Miyamoto K, et al. Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study). Jpn J Clin Oncol. 2018;48:777–80.PubMedCrossRef
79.
Martinelli G, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010;28:4480–4.PubMedCrossRef
80.
Buske C, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504–8.PubMedCrossRef
81.
Nooka AK, et al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:441–8.CrossRef
82.
83.
Pastore A, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111–22.PubMedCrossRef
84.
Jurinovic V, et al. Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the gallium trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy. Blood. 2019;134:122–122.CrossRef
85.
Lockmer S, et al. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Br J Haematol. 2020;188:259–67.PubMedCrossRef
86.
Montalbán C, et al. Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol. 2012;159:164–71.PubMedCrossRef
87.
Arcaini L, et al. Splenic marginal zone lymphoma: A prognostic model for clinical use. Blood. 2006;107:4643–9.PubMedCrossRef
88.
89.
Morel P, et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood. 2009;113:4163–70.PubMedCrossRef
90.
Solal-Céligny P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65.PubMedCrossRef
91.
Marcus R, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377:1331–44.PubMedCrossRef
92.
Hiddemann W, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36:2395–404.PubMedCrossRef
93.
Salles G, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42–51.PubMedCrossRef
94.
Bachy E, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019;37:2815–24.PubMedPubMedCentralCrossRef
95.
Flinn IW, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014a;123:2944–52.PubMedPubMedCentralCrossRef
96.
Rummel MJ, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–10.PubMedCrossRef
97.
Mir F, et al. Baseline SUVmax did not predict histological transformation in the phase 3 GALLIUM study in follicular lymphoma. Blood. 2020;135:1214–8.PubMedPubMedCentralCrossRef
98.
Lugtenburg EJ, et al. Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study. J Clin Oncol. 2019;37:7507–7507.CrossRef
99.
Hill BT, et al. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol. 2019;184:524–35.PubMedCrossRef
100.
Treon SP, et al. Extended rituximab therapy in Waldenström’s macroglobulinemia. Ann Oncol Off J Eur Soc Med Oncol. 2005;16:132–8.CrossRef
101.
Treon SP, et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol. 2011;154:357–62.PubMedCrossRef
102.
Dimopoulos MA, et al. Extended rituximab therapy for previously untreated patients with Waldenström’s macroglobulinemia. Clin Lymphoma. 2002;3:163–6.PubMedCrossRef
103.
Hochster H, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 study. J Clin Oncol. 2009;27:1607–14.PubMedPubMedCentralCrossRef
104.
Morschhauser F, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379:934–47.PubMedCrossRef
105.
Nastoupil LJ, et al. Results of a phase II study of obinutuzumab in combination with lenalidomide in previously untreated, high tumor burden follicular lymphoma (FL). Blood. 2019;134:125–125.CrossRef
106.
Cheson BD, Morschhauser F, Martin P. Management of adverse events from the combination of rituximab and lenalidomide in the treatment of patients with follicular and low-grade non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20:563–71.PubMedCrossRef
107.
Advani RH, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2014;32:912–8.PubMedCrossRef
108.
Conconi A, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741–5.PubMedCrossRef
109.
Zucca E, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: Improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35:1905–12.PubMedCrossRef
110.
Leonard JP, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37:1188–99.PubMedPubMedCentralCrossRef
111.
Dimopoulos MA, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med. 2018;378:2399–410.PubMedCrossRef
112.
Fischer K, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225–36.PubMedCrossRef
113.
Chihara D, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016;174:760–6.PubMedPubMedCentralCrossRef
114.
Chihara D, et al. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. J Clin Oncol. 2020;38:1527–8.PubMedPubMedCentralCrossRef
115.
Else M, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145:733–40.PubMedCrossRef
116.
Else M, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer. 2005;104:2442–8.PubMedCrossRef
117.
Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21:591–6.CrossRef
118.
Chadha P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005;106:241–6.PubMedCrossRef
119.
Park JH, et al. First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with Hcl. Blood. 2019;134:3998.CrossRef
120.
Vindi J, et al. A clinicogenetic risk model (m7-FLIPI) prospectively identifies one-half of patients with early disease progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2015;126:333–333.CrossRef
121.
Eskelund CW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903–10.PubMedCrossRef
122.
Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123:3247–54.PubMedCrossRef
123.
Chau K, et al. Outcomes of 210 patients with follicular and marginal zone lymphomas treated with 4 Gy of radiation therapy. Blood. 2019;134:2827.CrossRef
124.
Russo AL, et al. Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure. Int J Radiat Oncol Biol Phys. 2013;86:121–7.PubMedCrossRef
125.
Hoskin PJ, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15:457–63.PubMedCrossRef
126.
Hoskin P, et al. Long term follow-up of FoRT: a phase 3 multi-center prospective randomized trial of radiation therapy for follicular and marginal zone lymphoma. Hematol Oncol. 2019;37:219–20.CrossRef
127.
Brepoels L, et al. Aggressive and indolent non-Hodgkin’s lymphoma: response assessment by Integrated International Workshop Criteria. Leuk Lymphoma. 2007;48:1522–30.PubMedCrossRef
128.
Albano D, et al. Prognostic role of baseline 18 F-FDG PET/CT parameters in MALT lymphoma. Hematol Oncol. 2019;37:39–46.PubMedCrossRef
129.
Batlevi CL, et al. Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. Eur J Cancer. 2020b;126:78–90.PubMedPubMedCentralCrossRef
130.
Trotman J, et al. Prognostic value of PET-CT after fi rst-line therapy in patients with follicular lymphoma: A pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014;1:e17–27.PubMedCrossRef
131.
Trotman J, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018;19:1530–42.PubMedCrossRef
132.
Scherer F, Kurtz DM, Diehn M, Alizadeh AA. High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood. 2017;130:440–52.PubMedPubMedCentralCrossRef
133.
Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16:409–24.PubMedCrossRef
134.
135.
Roschewski M, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16:541–9.PubMedPubMedCentralCrossRef
136.
Spina V, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood. 2018;131:2413–25.PubMedCrossRef
137.
Sarkozy C, et al. The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. Oncotarget. 2017;8:8765–74.PubMedPubMedCentralCrossRef
138.
139.
140.
Pangalis GA, Angelopoulou MK, Vassilakopoulos TP, Siakantaris MP, Kittas C. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström’s macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol. 1999;36:104–14.PubMed
141.
Armand M, Besson C, Hermine O, Davi F. Hepatitis C virus—associated marginal zone lymphoma. Best Pract Res Clin Haematol. 2017;30:41–9.PubMedCrossRef
142.
143.
Kalpadakis C, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist. 2013;18:190–7.PubMedPubMedCentralCrossRef
144.
Kalpadakis C, et al. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. Blood. 2018;132:666–70.PubMedCrossRef
145.
Tsimberidou AM, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006;107:125–35.PubMedCrossRef
146.
Iannitto E, et al. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. Br J Haematol. 2018;183:755–65.PubMedCrossRef
147.
Targarona EM, Cerdán G, Gracia E, Rodríguez M, Trias M. Results of laparoscopic splenectomy for treatment of malignant conditions. HPB (Oxford). 2001;3:251–5.PubMedCrossRef
148.
149.
Fallah J, Olszewski AJ. Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base. Hematology. 2019;24:378–86.PubMedCrossRef
150.
Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J Infect. 2001;43:182–6.PubMedCrossRef
151.
Kyaw MH, et al. Evaluation of severe infection and survival after splenectomy. Am J Med. 2006;119:276.e1-276.e7.PubMedCrossRef
152.
Bagrodia N, et al. Morbidity and mortality following elective splenectomy for benign and malignant hematologic conditions analysis of the american college of surgeons national surgical quality improvement program data. JAMA Surg. 2014;149:1022–9.PubMedCrossRef
153.
Zaorsky NG, et al. Splenic irradiation for splenomegaly: a systematic review. Cancer Treat Rev. 2017;53:47–52.PubMedCrossRef
154.
Trip AK, et al. Radiation-induced dose-dependent changes of the spleen following postoperative chemoradiotherapy for gastric cancer. Radiother Oncol. 2015;116:239–44.PubMedCrossRef
155.
El Weshi A, et al. Low and medium dose spleen radiation therapy are able to induce long-term responses in splenic lymphoma with villous lymphocytes. Br J Haematol. 1998;103:1212–3.PubMedCrossRef
156.
157.
Nakamura S, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61:507–13.PubMedCrossRef
158.
Ohkubo Y, et al. Radiotherapy for localized gastric mucosa-associated lymphoid tissue lymphoma: long-term outcomes over 10 years. J Radiat Res. 2017;58:537.PubMedPubMedCentralCrossRef
159.
Zullo A, et al. Effects of helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010;8:105–10.PubMedCrossRef
160.
Liu H, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357:39–40.PubMedCrossRef
161.
Lévy M, et al. Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. Leuk Lymphoma. 2013;54:940–4.PubMedCrossRef
162.
Ye H, et al. MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J Pathol. 2005;205:293–301.PubMedCrossRef
163.
Koch P, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the german multicenter study GIT NHL 01/92. J Clin Oncol. 2001;19:3861–73.PubMedCrossRef
164.
Papaxoinis G, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma. 2006;47:2140–6.PubMedCrossRef
165.
Marks E, Shi Y. Duodenal-type follicular lymphoma a clinicopathologic review. Arch Pathol Lab Med. 2018;142:542–7.PubMedCrossRef
166.
Salem P, et al. Primary small intestinal lymphoma in adults. A comparative study of IPSID versus non-IPSID in the middle east. Cancer. 1987;59:1670–6.PubMedCrossRef
167.
Li G, Hansmann M-L, Zwingers T, Lennert K. Primary lymphomas of the lung: morphological, immunohistochemical and clinical features. Histopathology. 1990;16:519–31.PubMedCrossRef
168.
169.
Leyfman Y, et al. Expectant management of extranodal marginal zone lymphoma of bronchial-associated lymphoid tissue (BALT). Blood. 2019;134:2826–2826.CrossRef
170.
Hollender A, et al. Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann Oncol Off J Eur Soc Med Oncol. 2002;13:1099–107.CrossRef
171.
Simon L, et al. Bing-Neel syndrome, a rare complication of waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO). Haematologica. 2015;100:1587–94.PubMedPubMedCentralCrossRef
172.
Castillo JJ, et al. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016;172:709–15.PubMedCrossRef
173.
174.
Cabannes-Hamy A, et al. Efficacy of ibrutinib in the treatment of Bing-Neel syndrome. Am J Hematol. 2016;91:E17–9.PubMedCrossRef
175.
176.
de la Fuente MI, et al. Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences. Leuk Lymphoma. 2017;58:882–8.PubMedCrossRef
177.
Edinger JT, Kant JA, Swerdlow SH. Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets. Am J Surg Pathol. 2010;34:1830–41.PubMedCrossRef
178.
Skala SL, Hristov B, Hristov AC. Primary cutaneous follicle center lymphoma. Arch Pathol Lab Med. 2018;142:1313–21.PubMedCrossRef
179.
180.
Goodlad JR, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the highlands of Scotland. Am J Surg Pathol. 2000;24:1279–85.PubMedCrossRef
181.
Suárez AL, et al. Primary cutaneous B-cell lymphomas: Part II. Therapy and future directions. J Am Acad Dermatol. 2013;69:343.e1-343.e11.PubMedCrossRef
182.
Holm F, et al. Ocular adnexal lymphoma in Denmark: a nationwide study of 387 cases from 1980 to 2017. Br J Ophthalmol. 2020;85:220.
183.
Rehn S, et al. Radiotherapy dose and volume de-escalation in ocular adnexal lymphoma. Anticancer Res. 2020;40:4041–6.PubMedCrossRef
184.
Ferreri AJM, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004;96:586–94.PubMedCrossRef
185.
Ferreri AJM, et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol. 2005;23:5067–73.PubMedCrossRef
186.
Casulo C, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516–22.PubMedPubMedCentralCrossRef
187.
Seymour JF, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104:1202–8.PubMedPubMedCentralCrossRef
188.
189.
Freeman CL, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019;134:761–4.PubMedCrossRef
190.
Luminari S, et al. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. Blood. 2019;134:798–801.PubMedCrossRef
191.
Ghielmini M, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood. 2004;103:4416–23.PubMedCrossRef
192.
Sehn LH, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015;33:3467–74.PubMedPubMedCentralCrossRef
193.
Rummel M, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17:57–66.PubMedCrossRef
194.
von Keudell G, Moskowitz AJ. The role of PI3K inhibition in lymphoid malignancies. Curr Hematol Malig Rep. 2019;14:405–13.CrossRef
195.
Flinn IW, et al. DYNAMO: a Phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma. J Clin Oncol. 2019a;37:912–22.PubMedCrossRef
196.
Dreyling M, et al. Phosphatidylinositol 3-kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35:3898–905.PubMedCrossRef
197.
Flinn IW, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014b;123:3406–13.PubMedPubMedCentralCrossRef
198.
Lampson BL, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195–203.PubMedPubMedCentralCrossRef
199.
Coutre S, et al. Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials. J Clin Oncol. 2015;33:e18030–e18030.CrossRef
200.
O’Brien SM, et al. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015;126:2686–94.PubMedPubMedCentralCrossRef
201.
Burris HA, et al. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018;19:486–96.PubMedCrossRef
202.
Pagel J, et al. (2020) The PI3KΔ inhibitor ME-401 is well-tolerated on intermittent… EHA library. Pagel J. 2020;2020:293663.
203.
Forero-Torres A, et al. Parsaclisib, a potent and highly selective PI3Kd inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019;133:1742–52.PubMedPubMedCentralCrossRef
204.
205.
Gachard N, et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia. 2013;27:183–99.PubMedCrossRef
206.
Noy A, et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv. 2020;4:5773–84.PubMedPubMedCentralCrossRef
207.
208.
209.
Davids MS, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35:826–33.PubMedPubMedCentralCrossRef
210.
Castillo J, et al. Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2019;19:e39–40.CrossRef
211.
Seymour JF, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107–20.PubMedCrossRef
212.
213.
Morschhauser F, et al. Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma. Blood. 2019a;134:123–123.CrossRef
214.
Dornan D, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114:2721–9.PubMed
215.
Sehn LH, et al. Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. J Clin Oncol. 2018;36:7507–7507.CrossRef
216.
Morschhauser F, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019b;6:e254–65.PubMedCrossRef
217.
Schuster SJ, et al. Mosunetuzumab induces complete remissions in poor prognosis non-hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134:6.CrossRef
218.
Advani R, et al. The first-in-class anti-CD47 antibody HU5F9-G4 + rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: interim phase 1B/2 results. Hematol Oncol. 2019;37:89–90.CrossRef
219.
Emmanouilides C, et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin’s lymphoma. Cancer Biother Radiopharm. 2007;22:684–91.PubMed
220.
McDonald GB, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003–2007 versus 2013–2017 cohorts. Ann Intern Med. 2020;172:229–39.PubMedPubMedCentralCrossRef
221.
Jurinovic V, et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the german low grade lymphoma study group. Biol Blood Marrow Transplant. 2018;24:1172–9.PubMedCrossRef
222.
Smith SM, et al. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer. 2018;124:2541–51.PubMedCrossRef
223.
Casulo C, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a national lymphocare study and center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2018;24:1163–71.PubMedCrossRef
224.
Ladetto M, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall surviva. Blood. 2008;111:4004–18.PubMedCrossRef
225.
Gyan E, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 year. Blood. 2009;113:995–1001.PubMedCrossRef
226.
Dahi PB, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20:2004–9.PubMedPubMedCentralCrossRef
227.
Majhail NS, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2015;21:1–7.CrossRef
228.
229.
Sureda A, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018;124:1733–42.PubMedCrossRef
230.
Shah NN, et al. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv. 2018;2:933–40.PubMedPubMedCentralCrossRef
231.
Kanate AS, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127:938–47.PubMedPubMedCentralCrossRef
232.
Ghosh N, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a center for international blood and marrow transplant research analysis. J Clin Oncol. 2016;34:3141–9.PubMedPubMedCentralCrossRef
233.
Sauter CS, et al. A Phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with BCell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. Biol Blood Marrow Transplant. 2014;20:354–60.PubMedCrossRef
234.
235.
236.
237.
Jacobson CA, et al. Interim analysis of ZUMA-5: a phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL). J Clin Oncol. 2020;38:8008.CrossRef
238.
Lee DW, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–38.PubMedCrossRef
239.
Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2017;15:31–46.PubMedCrossRef
240.
Herfarth K, et al. Rituximab with involved field irradiation for early-stage nodal follicular lymphoma. HemaSphere. 2018;1:e160.CrossRef
241.
Flinn IW, et al. First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019b;37:984–91.PubMedPubMedCentralCrossRef
242.
Sehn LH, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17:1081–93.PubMedCrossRef
Metadata
Title
How we treat mature B-cell neoplasms (indolent B-cell lymphomas)
Authors
Melissa Lumish
Lorenzo Falchi
Brandon S. Imber
Michael Scordo
Gottfried von Keudell
Erel Joffe
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2021
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-020-01018-6

Other articles of this Issue 1/2021

Journal of Hematology & Oncology 1/2021 Go to the issue

Letter to the Editor

WDR26 and MTF2 are therapeutic targets in multiple myeloma

Research

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

Research

Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study

Letter to the Editor

Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort

Review

The emerging role of KDM5A in human cancer

Review

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits